These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32407526)

  • 1. Ruxolitinib for steroid-resistant acute GVHD.
    Risitano AM; Peffault de Latour R
    Blood; 2020 May; 135(20):1721-1722. PubMed ID: 32407526
    [No Abstract]   [Full Text] [Related]  

  • 2. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results.
    González Vicent M; Molina B; González de Pablo J; Castillo A; Díaz MÁ
    Am J Hematol; 2019 Mar; 94(3):319-326. PubMed ID: 30536806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience.
    Uygun V; Karasu G; Daloğlu H; Öztürkmen S; Kılıç SÇ; Yalçın K; Çelen SS; Hazar V; Yeşilipek A
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28190. PubMed ID: 31981413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
    von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
    BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.
    Abedin S; McKenna E; Chhabra S; Pasquini M; Shah NN; Jerkins J; Baim A; Runaas L; Longo W; Drobyski W; Hari PN; Hamadani M
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1689-1694. PubMed ID: 30965140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond ruxolitinib in steroid-refractory acute graft-versus-host disease.
    Lee CJ; Pusic I; Savani BN
    Br J Haematol; 2021 Nov; 195(3):306-307. PubMed ID: 34402041
    [No Abstract]   [Full Text] [Related]  

  • 7. Ruxolitinib for steroid-refractory acute graft-versus-host disease.
    Toama W; Fiala M; Pusic I; Westervelt P; Dipersio JF; Schroeder M
    Transpl Int; 2020 Feb; 33(2):244-246. PubMed ID: 31755139
    [No Abstract]   [Full Text] [Related]  

  • 8. Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide.
    Zhao JY; Liu SN; Xu LP; Zhang XH; Wang Y; Chen YH; Liu KY; Huang XJ; Mo XD
    Ann Hematol; 2021 Jan; 100(1):169-180. PubMed ID: 33159239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.
    Maffini E; Giaccone L; Festuccia M; Brunello L; Buondonno I; Ferrero D; Boccadoro M; Dellacasa C; Busca A; Novero D; Bruno B
    J Hematol Oncol; 2016 Aug; 9(1):67. PubMed ID: 27502249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.
    Przepiorka D; Luo L; Subramaniam S; Qiu J; Gudi R; Cunningham LC; Nie L; Leong R; Ma L; Sheth C; Deisseroth A; Goldberg KB; Blumenthal GM; Pazdur R
    Oncologist; 2020 Feb; 25(2):e328-e334. PubMed ID: 32043777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients.
    Khandelwal P; Teusink-Cross A; Davies SM; Nelson AS; Dandoy CE; El-Bietar J; Marsh RA; Kumar AR; Grimley MS; Jodele S; Myers KC
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1122-1127. PubMed ID: 28344057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ruxolitinib for treatment of GvHD in patients with myelofibrosis].
    Mori Y
    Rinsho Ketsueki; 2019; 60(8):953-959. PubMed ID: 31484895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
    Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
    Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
    Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
    Front Immunol; 2021; 12():673636. PubMed ID: 34276662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
    Wu H; Shi J; Luo Y; Tan Y; Zhang M; Lai X; Yu J; Liu L; Fu H; Huang H; Zhao Y
    JAMA Netw Open; 2021 Jan; 4(1):e2034750. PubMed ID: 33502484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruxolitinib for Therapy of Graft-versus-Host Disease.
    Neumann T; Schneidewind L; Weigel M; Plis A; Vaizian R; Schmidt CA; Krüger W
    Biomed Res Int; 2019; 2019():8163780. PubMed ID: 30956985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level.
    Modemann F; Ayuk F; Wolschke C; Christopeit M; Janson D; von Pein UM; Kröger N
    Bone Marrow Transplant; 2020 Dec; 55(12):2286-2293. PubMed ID: 32447349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruxolitinib treatment for GvHD in patients with myelofibrosis.
    Mori Y; Ikeda K; Inomata T; Yoshimoto G; Fujii N; Ago H; Teshima T
    Bone Marrow Transplant; 2016 Dec; 51(12):1584-1587. PubMed ID: 27721370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-vs-Host Disease-Another Hopeful Step Forward.
    Alvarnas JC
    JAMA Netw Open; 2021 Jan; 4(1):e2035719. PubMed ID: 33502479
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficiency and Toxicity of Ruxolitinib as the Salvage Treatment in Steroid-Refractory Acute Graft-Versus-Host Disease after Haplo-Identical Stem Cell Transplantation.
    Liu Y; Fan Y; Zhang W; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
    Transplant Cell Ther; 2021 Apr; 27(4):332.e1-332.e8. PubMed ID: 33836880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.